Eli Lilly and Company revised earnings guidance for the year 2022. For the year, the company expects revised revenue to be in the range of $28.5 billion to $29.0 billion and earnings per share to be in the range of $6.50 to $6.65 compared to previously expected revenue to be in the range of $28.8 billion to $29.3 billion and earnings per share to be in the range of $6.96 to $7.11.